Advertisement

Cardiovascular Drugs and Therapy

, Volume 4, Supplement 5, pp 979–982 | Cite as

Renal effects of calcium entry blockers

  • Luis M. Ruilope
  • Jose M. Alcazar
Nifedipine: Renal Effects

Summary

Calcium entry blockers exert several characteristic effects on renal function that contribute to their blood-pressure lowering capacity. They are able to dilate renal vasculature and, in certain circumstances, can increase the glomerular filtration rate, both effects being dependent on the preexisting vascular tone. Calcium blockers are also able to increase renal sodium excretion, mainly through a direct tubular effect that remains during the chronic administration of these drugs. These effects clearly differentiate calcium entry blockers from nonspecific vasodilators and contribute to their effectiveness when they are used as first-step drugs in the therapy of arterial hypertension.

Key Words

calcium antagonists renal function sodium diuresis tubular effect of calcium antagonists 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fleckenstein A. History of calcium antagonists.Circ Res 1983;52(Suppl 1):3–16.Google Scholar
  2. 2.
    Guyton AC, Coleman TG, Cowley AW, et al. Arterial pressure regulation; overriding dominance of the kidneys in long-term regulation and in hypertension.Am J Med 1972; 52:584–594.CrossRefPubMedGoogle Scholar
  3. 3.
    Hollenberg NK. The kidney and effective antihypertensive therapy.Am J Cardiol 1985;56:52H-55H.CrossRefPubMedGoogle Scholar
  4. 4.
    Koch-Weser J. Vasodilator drugs in the treatment of hypertension.Arch Intern Med 1974;133:1017–1027.CrossRefPubMedGoogle Scholar
  5. 5.
    Finnerty FA Jr. Relationship of extracellular fluid volume to the development on drug resistance in the hypertensive patients.Am Heart J 1971;81:564–565.Google Scholar
  6. 6.
    Zius GR. Alterations in renal function, during vasodilator therapy. In: Wesson LG, Fanelli GM, eds.Recent advances in renal physiology and pharmacology. Baltimore. University Park Press, 1974;165–172.Google Scholar
  7. 7.
    Greene JA Jr. Effects of diazoxide on renal function in the dog.Proc Soc Exp Biol Med 1967;125:375–379.PubMedGoogle Scholar
  8. 8.
    Romero JC, Ruilope LM, Bentley MD, et al. Comparison of the effects of calcium antagonists and converting enzyme inhibitors on renal function under normal and hypertensive conditions.Am J Cardiol 1988;62:59G-68G.CrossRefPubMedGoogle Scholar
  9. 9.
    Ruilope LM, Garcia-Robles R, Miranda B, et al. Renal effects of fenoldopam in refractory hypertension.J Hypertens 1988;6:665–670.PubMedGoogle Scholar
  10. 10.
    Romero JC, Raji L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension.Hypertension 1987;10:140–151.PubMedGoogle Scholar
  11. 11.
    Loutzenhiser R, Epstein M. Effects of calcium antagonists on renal hemodynamics.Am J Physiol 1985;249:F619-F629.PubMedGoogle Scholar
  12. 12.
    Blackshear JL, Garnic D, Williams GH, et al. Exaggerated renal vasodilator response to calcium entry blockade in firstdegree relatives of essential hypertensive subjects.Hypertension 1987;9:384–389.PubMedGoogle Scholar
  13. 13.
    Leonetti G, Cuspidi C, Sampieri L, et al. Comparison of cardiovascular, renal and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects.J Cardiovasc Pharmacol 1982;4 (Suppl 3):319–323.Google Scholar
  14. 14.
    Wallia R, Greenberg A, Puschett JB. Renal hemodynamic effects and tubular transport effects of nitrendipine.J Lab Clin Med 1985;105:498–503.PubMedGoogle Scholar
  15. 15.
    Ruilope LM, Miranda B, Garcia-Robles R, et al. Effects of nisoldipine on renal function in normal volunteers and essential hypertensive patients.J Cardiovasc Pharmacol 1989; 13:90–93.PubMedGoogle Scholar
  16. 16.
    Sakura T, Kurita T, Nagano S, Sonoda T. Antihypertensive vasodilating and sodium diuretic actions of D-eis isomer of benzothiazepine derivative (CRD-401).Acta Biol Jpn 1972;18:695–701.Google Scholar
  17. 17.
    Yokoyama S, Kaburagi T. Clinical effects of intravenous nifedipine on renal function.J Cardiovasc Pharmacol 1983;5:67–71.PubMedGoogle Scholar
  18. 18.
    Van Schaik BAM, Van Nistelrooy AEJ, Geyskes GG. Antihypertensive and renal effects of nicardipine.Br J Clin Pharmacol 1984;18:57–63.PubMedGoogle Scholar
  19. 19.
    Loutzenhiser R, Epstein M, Horton C, Sonke P. Reversal by the calcium antagonist nisoldipine of norepinephrineinduced reduction of glomerular filtration rate: Evidence for preferential antagonism of preglomerular vasoconstriction.J Pharmacol Exp Ther 1985;232:382–387.PubMedGoogle Scholar
  20. 20.
    Loutzenhiser R, Epstein M. Modification of the renal hemodynamic response to vasoconstrictors by calcium antagonist.Am J Nephrol 1987;7(Suppl 1):7–16.PubMedGoogle Scholar
  21. 21.
    Montanari A, Vallisa D, Ragni G, et al. Abnormal renal responses to calcium entry blockade in normotensive offspring of hypertensive parents.Hypertension 1988;12:498–505.PubMedGoogle Scholar
  22. 22.
    Epstein M. Future prospects for calcium antagonists.Consultant 1987;27(Suppl 12):45–47.Google Scholar
  23. 23.
    Baumelou A, Bentchikou A, Vray M, et al. Nitrendipine in patients with renal disease.J Cardiovasc Pharmacol 1987;9(Suppl 4):S174-S177.Google Scholar
  24. 24.
    Rodicio JL, Ruilope LM. The role of antihypertensive therapy in the progression of chronic renal failure. In: Hansson L, ed.Hypertension Annual. London: Gower Academic Journals, 1988;47–58.Google Scholar
  25. 25.
    Eliahou HE, Cohen D, Helberg B, et al. Effect of the calcium channel blocker nisoldipine on the progression of chronic renal failure in man.Am J Nephrol 1988;8:285–290.PubMedGoogle Scholar
  26. 26.
    Tolins JP, Schultz P, Raij L, Mechanisms of hypertensive glomerular injury.Am J Cardiol 1988;62:54G-58G.CrossRefPubMedGoogle Scholar
  27. 27.
    Keeton TK, Campbell WB. The pharmacologic alteration of renin release.Pharmacol Rer 1981;31:81–227.Google Scholar
  28. 28.
    Bauer JH, Sunderrajan S, Reams G. Effect of calcium entry blockers on renin-angiotensin-aldosterone system, renal function and hemodynamics, salt and water excretion and body fluid composition.Am J Cardiol 1985;56:62H-65H.CrossRefPubMedGoogle Scholar
  29. 29.
    MacGregor GA. Sodium balance and calcium antagonists in hypertension.Consultant 1987;27(Suppl 12)29–32.Google Scholar
  30. 30.
    Nicholson JP, Resnick LM, Laragh JH. The antihypertensive effect of verapamil at extremes of dietary sodium intake.Ann Intern Med 1987;107:329–333.PubMedGoogle Scholar
  31. 31.
    Nicholson JP, Resnick LM, Laragh JH. Hydrochlorothiazide is not additive to verapamil in treating essential hypertension.Arch Intern Med 1989;149:125–126.CrossRefPubMedGoogle Scholar
  32. 32.
    Husted SE, Nielsen HK, Christensen CK, Lederballe-Pedersen O. Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a betaadrenoceptor blocking agent.Eur J Clin Pharmacol 1982;22:101–103.CrossRefPubMedGoogle Scholar
  33. 33.
    Bauer JH, Reams G. Short and long-term effects of calcium entry blockers on the kidney.Am J Cardiol 1987;59:66A-71A.CrossRefPubMedGoogle Scholar
  34. 34.
    MacGregor GA, Pevahouse JB, Cappuccio FP, Markandu ND. Nifedipine, sodium intake, diuretics and sodium balance.Am J Nephrol 1987;7(Suppl 1):44–48.CrossRefPubMedGoogle Scholar
  35. 35.
    Ruilope LM, Miranda B, Oliet A, et al. Persistence of the natriuretic effect of calcium entry blockers.J Cardiovasc Pharmacol 1988;12(Suppl 4):S136-S139.PubMedCrossRefGoogle Scholar
  36. 36.
    Krusell LR, Jespersen LT, Schmitz A, et al. Repetitive natriuresis and blood pressure. Long-term calcium entry blockade with isradipine.Hypertension 1987;10:577–581.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • Luis M. Ruilope
    • 1
  • Jose M. Alcazar
    • 1
  1. 1.Department of NephrologyHypertension UnitMadridSpain

Personalised recommendations